Differential effects of milrinone and dobutamine on right ventricular preload, afterload and systolic performance in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy

https://doi.org/10.1016/0002-9149(87)90616-3Get rights and content

Abstract

To compare the effects of intravenous dobutamine and milrinone on right ventricular (RV) systolic function, 14 patients with severe congestive heart failure underwent simultaneous radionuclide-hemodynamic study. Patients were randomized to receive intravenous milrinone (50 μg/kg bolus then 0.5 μg/kg/ min) or dobutamine (2.5 to 15 μg/kg/min) to achieve equal increases in cardiac output. Both drugs significantly improved cardiac performance, with identical 24% increases in mean cardiac index (p < 0.05 vs baseline; difference not significant for milrinone vs dobutamine) and no change in heart rate. Neither drug substantially altered RV preload, as reflected by mean right atrial pressure and RV end-diastolic volume. Both drugs caused similar increases in RV ejection fraction (mean ± standard deviation; dobutamine: 0.32 ± 0.09 to 0.40 ± 0.11; p < 0.05; milrinone: 0.35 ± 0.19 to 0.43 ± 0.21; p < 0.05) resulting from reductions in RV end-systolic volume. RV afterload reduction contributed substantially to drug effect on RV systolic performance in patients treated with milrinone but not those treated with dobutamine. With doses effecting equal increases in cardiac index and RV systolic performance, pulmonary artery end-systolic pressure was significantly reduced by milrinone (40 ± 12 to 33 ± 12 mm Hg; p < 0.05), but not by dobutamine. Thus, in patients with congestive heart failure milrinone's effect on RV systolic function is explainable, at least in part, by RV afterload reduction, whereas RV inotropic augmentation contributed more strongly to dobutamine's effect.

References (25)

Cited by (81)

  • Key Concepts Surrounding Cardiogenic Shock

    2022, Current Problems in Cardiology
  • Right heart failure: A narrative review for emergency clinicians

    2022, American Journal of Emergency Medicine
    Citation Excerpt :

    However, dobutamine has a half-life of 2 min compared to the half-life of milrinone which is 2–4 h [67]. While direct comparisons of these medications specifically for RHF are sparse, the limited evidence on RHF and trials in patients with advanced decompensated heart failure in general show similar clinical outcomes with either medication [69-71]. Given the shorter half-life, lower cost, and ED availability, dobutamine may be a preferable choice for use in the ED.

  • Critical Care Management of the Patient with Pulmonary Hypertension

    2021, Clinics in Chest Medicine
    Citation Excerpt :

    Dobutamine improves hemodynamics in severe RV infarction and in PH after liver transplantation.37,56 Milrinone, a selective PDE-3 inhibitor, often is used in pulmonary vascular dysfunction due to LV dysfunction or post–cardiac transplant, because it reduces PA pressures and improves RV function.57,58 Its use in PAH or isolated RV failure can be limited by systemic hypotension or its effects on an unloaded LV.

View all citing articles on Scopus

This work was performed when Dr. Eichhorn and Dr. Weiland were recipients of fellowship awards from the American Heart Association, Massachusetts Affiliate.

View full text